ATE444972T1 - ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTOR - Google Patents
ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTORInfo
- Publication number
- ATE444972T1 ATE444972T1 AT03725701T AT03725701T ATE444972T1 AT E444972 T1 ATE444972 T1 AT E444972T1 AT 03725701 T AT03725701 T AT 03725701T AT 03725701 T AT03725701 T AT 03725701T AT E444972 T1 ATE444972 T1 AT E444972T1
- Authority
- AT
- Austria
- Prior art keywords
- higf
- antibodies
- igf
- human
- ßinsulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002129046 | 2002-04-30 | ||
PCT/JP2003/005505 WO2003093317A1 (fr) | 2002-04-30 | 2003-04-30 | Anticorps pour facteur de croissance humain semblable a l'insuline |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE444972T1 true ATE444972T1 (de) | 2009-10-15 |
Family
ID=29397291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03725701T ATE444972T1 (de) | 2002-04-30 | 2003-04-30 | ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTOR |
Country Status (9)
Country | Link |
---|---|
US (1) | US7438911B2 (de) |
EP (1) | EP1505075B1 (de) |
JP (1) | JP4335130B2 (de) |
AT (1) | ATE444972T1 (de) |
AU (1) | AU2003231554A1 (de) |
CA (1) | CA2483848C (de) |
DE (1) | DE60329589D1 (de) |
ES (1) | ES2333952T3 (de) |
WO (1) | WO2003093317A1 (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004265152A1 (en) | 2003-08-13 | 2005-02-24 | Pfizer Products Inc. | Modified human IGF-1R antibodies |
US20060263362A1 (en) * | 2003-08-21 | 2006-11-23 | Atsushi Ochiai | Cancer metastasis inhibitor |
US7498415B2 (en) | 2003-09-24 | 2009-03-03 | Kyowa Hakko Kogyo Co., Ltd. | Recombinant antibody against human insulin-like growth factor |
US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
WO2006060419A2 (en) | 2004-12-03 | 2006-06-08 | Schering Corporation | Biomarkers for pre-selection of patients for anti-igf1r therapy |
KR101372690B1 (ko) | 2005-12-13 | 2014-03-17 | 아스트라제네카 아베 | 인슐린 유사 성장 인자에 특이적인 결합 단백질 및 이의용도 |
SI1979001T1 (sl) * | 2005-12-13 | 2012-08-31 | Medimmune Ltd | Vezni proteini specifiäśno za inzulinu podobne rastne faktorje in njih uporaba |
EP2010567A2 (de) * | 2006-04-07 | 2009-01-07 | The Government of the United States of America as Represented by The Department of Health and Human Services | Antikörperzusammensetzungen und verfahren zur behandlung von neoplasien |
WO2008152422A2 (en) * | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Binding proteins specific for insulin-like growth factors and uses thereof-909 |
PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
KR20110014607A (ko) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
AU2009244091B2 (en) * | 2008-05-09 | 2014-11-27 | Commonwealth Scientific And Industrial Research Organisation | IGF-II/GF-IIE binding proteins |
SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
SG192489A1 (en) | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
WO2010045315A1 (en) | 2008-10-14 | 2010-04-22 | Dyax Corp. | Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
KR101827332B1 (ko) | 2008-12-12 | 2018-02-09 | 베링거 인겔하임 인터내셔날 게엠베하 | 항-igf 항체 |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
RU2012112550A (ru) * | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
PT3023438T (pt) | 2009-09-03 | 2020-05-08 | Merck Sharp & Dohme | Anticorpos anti-gitr |
US9056907B2 (en) | 2009-10-07 | 2015-06-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human domain antibodies against components of the human insulin-like growth factor (IGF) system |
WO2011047262A2 (en) * | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CN102918059A (zh) * | 2009-12-29 | 2013-02-06 | 协和发酵麒麟株式会社 | 抗cd27抗体 |
PE20131412A1 (es) | 2010-08-03 | 2014-01-19 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CA2816803A1 (en) * | 2010-11-02 | 2012-05-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
CN102520190B (zh) * | 2011-12-15 | 2014-03-05 | 中国人民解放军总医院 | 一种人胰岛素样生长因子ⅱ酶联免疫分析检测试剂盒 |
MX2014008101A (es) | 2011-12-30 | 2014-09-25 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17. |
WO2014071074A2 (en) | 2012-11-01 | 2014-05-08 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
EP2970459A2 (de) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Gegen il-1beta und il-17 gerichtete duale spezifische bindungsproteine |
RU2016138744A (ru) * | 2014-04-10 | 2018-05-11 | Оби Фарма Инк. | Антитела, фармацевтические композиции и их применения |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985000831A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
AU1232188A (en) * | 1987-05-29 | 1988-12-01 | Mallinckrodt, Inc. | Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i |
CA2058041A1 (en) * | 1990-06-27 | 1991-12-28 | Katsuichi Sakano | Anti-igf-ii monoclonal antibody |
WO1995025794A1 (fr) * | 1994-03-23 | 1995-09-28 | Japan Clinical Laboratories | Anticorps monoclonal anti-igf-i |
US20060263362A1 (en) * | 2003-08-21 | 2006-11-23 | Atsushi Ochiai | Cancer metastasis inhibitor |
-
2003
- 2003-04-30 ES ES03725701T patent/ES2333952T3/es not_active Expired - Lifetime
- 2003-04-30 EP EP03725701A patent/EP1505075B1/de not_active Expired - Lifetime
- 2003-04-30 DE DE60329589T patent/DE60329589D1/de not_active Expired - Lifetime
- 2003-04-30 JP JP2004501456A patent/JP4335130B2/ja not_active Expired - Fee Related
- 2003-04-30 WO PCT/JP2003/005505 patent/WO2003093317A1/ja active Application Filing
- 2003-04-30 CA CA2483848A patent/CA2483848C/en not_active Expired - Fee Related
- 2003-04-30 AU AU2003231554A patent/AU2003231554A1/en not_active Abandoned
- 2003-04-30 US US10/513,148 patent/US7438911B2/en not_active Expired - Fee Related
- 2003-04-30 AT AT03725701T patent/ATE444972T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ES2333952T3 (es) | 2010-03-03 |
JP4335130B2 (ja) | 2009-09-30 |
CA2483848C (en) | 2012-08-21 |
DE60329589D1 (de) | 2009-11-19 |
US7438911B2 (en) | 2008-10-21 |
WO2003093317A1 (fr) | 2003-11-13 |
EP1505075B1 (de) | 2009-10-07 |
US20060165695A1 (en) | 2006-07-27 |
EP1505075A1 (de) | 2005-02-09 |
CA2483848A1 (en) | 2003-11-13 |
EP1505075A4 (de) | 2006-06-21 |
JPWO2003093317A1 (ja) | 2005-09-08 |
AU2003231554A1 (en) | 2003-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE444972T1 (de) | ANTIKÖRPER GEGEN DEN HUMANEN ßINSULIN-LIKEß WACHSTUMSFAKTOR | |
EA200900177A1 (ru) | Замещенные ациланилиды и способы их применения | |
WO2008065378A3 (en) | Binding members for interleukin-6 | |
MX2009003093A (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
EP2535353A8 (de) | An hGM-CSF bindende monoklonale Antikörper und medizinische Zusammensetzungen damit | |
SG147444A1 (en) | Anti-ox40l antibodies | |
UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
ATE536376T1 (de) | Humanes bindungsmolekül gegen cd1a | |
EA200900345A1 (ru) | Замещенные ациланилиды и способы их применения | |
EA200700202A1 (ru) | Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей | |
TW200716612A (en) | Pyrimidine compounds | |
MX2009006066A (es) | Tratamiento de cerdos con el antigeno pcv. | |
MX2007000304A (es) | Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos. | |
CY1111714T1 (el) | Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf). | |
EA200901211A1 (ru) | Антигены белка с5 и их применение | |
WO2007025977A3 (en) | Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis | |
EA201000630A1 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для понижения уровней липидов в крови | |
ATE412414T1 (de) | 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen | |
WO2010075280A3 (en) | Coumarin-based compounds for the treatment of alzheimer's disease and cancer | |
ATE520032T1 (de) | Differentielle cytokinexpression bei einer menschlichen krebserkrankung | |
HK1175495A1 (en) | New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer | |
BR0307629A (pt) | Métodos e composições para tratar condições hiperproliferativas | |
ATE510536T1 (de) | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen | |
CY1111353T1 (el) | Χρηση ενωσεων κααλαλιδης για την παραγωγη φαρμακου για τη θεραπεια της ψωριασης | |
WO2010036567A3 (en) | Harmine compounds for promoting bone growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |